The DOI matches its Crossref record; 29 of the 31 references it cites were found in a registry or an index.
Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
Open accessAbstract
Objectives This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure.Background Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes.Methods We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE.Results Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated.Conclusions Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with T2DM and advanced HF, insulin use is independently associated with a significantly worse prognosis.552”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [552]
In the citing paper
“A small randomized, placebo-controlled trial of albiglutide in HFrEF showed no effect on left ventricular function and 6-minute walk distance.190”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,218
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,069
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 14×
“This myocardial energy depletion is thought to be a key contributor to the progressive impairment in myocardial systolic function that characterizes HFrEF.”
BackgroundInfluentialRector, T. S., & Cohn, J. N. (1992) · American Heart Journal · doi:10.1016/0002-8703(92)90986-6 · Cited by 1,020
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Patients' self-assessment of their congestive heart failure
Ts, R. (1987) · Medical Entomology and Zoology · Cited by 862
Fatty Acid Oxidation Enzyme Gene Expression Is Downregulated in the Failing Heart
Sack, M. N., Rader, T. A., Park, S., Bastin, J., McCune, S. A., & Kelly, D. P. (1996) · Circulation · doi:10.1161/01.cir.94.11.2837 · Cited by 678
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Mitochondrial energy metabolism in heart failure: a question of balance
Huss, J. M., & Kelly, D. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24405 · Cited by 532
Graham, D. J., Ouellet‐Hellstrom, R., MaCurdy, T. E., Ali, F. N., Sholley, C., Worrall, C. M., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512
Cited by
Sorted by citations
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure
Tassell, B. W. V., Canada, J. M., Carbone, S., Trankle, C. R., Buckley, L. F., Oddi, C., Abouzaki, N. A., Dixon, D. L., Kadariya, D., Christopher, S., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004373 · Cited by 248
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.014 · Cited by 236
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.010 · Cited by 196
Seferovic, P. M., Coats, A. J. S., Ponikowski, P. P., Filippatos, G. S., Huelsmann, M., Jhund, P. S., Polovina, M. M., Michel Komajda, N., Seferović, J. P., Sarı, İ., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 183
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 136
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
von Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 119
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 101
Mitochondrial dysfunction and its impact on diabetic heart
Verma, S. K., Garikipati, V. N. S., & Kishore, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.021 · Cited by 94
Neves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., & Ferreira, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 87
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 81
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 79
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
GLP-1 receptor agonists and heart failure in diabetes
Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 65
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 65
Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy
Moellmann, J., Klinkhammer, B. M., Onstein, J., Stöhr, R., Jankowski, V., Jankowski, J., Lebherz, C., Tacke, F., Marx, N., Boor, P., et al. (2018) · Diabetes · doi:10.2337/db17-1212 · Cited by 60
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 61
Docherty, K. F., Campbell, R. T., Brooksbank, K. J. M., Dreisbach, J. G., Forsyth, P., Godeseth, R. L., Hopkins, T., Jackson, A. M., Lee, M. M. Y., McConnachie, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054892 · Cited by 56
Du, X., Zhang, H., Zhang, W., Wang, Q., Wang, W., Ge, G., Bai, J., Guo, X., Zhang, Y., Jiang, X., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105732 · Cited by 55
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 61
Kumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 52
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 50
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Wang, J., Yu, M., Xu, J., Cheng, Y., Li, X., Wei, G., Wang, H., Kong, H., & Xie, W. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0496-y · Cited by 42
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 43
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
Nguyễn, T. D., Shingu, Y., Amorim, P., Schenkl, C., Schwarzer, M., & Doenst, T. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9795-z · Cited by 41
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Koška, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 34
Singh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 31
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 25
Yeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25
Merza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 24
Zhao, H., Liu, Y., Liu, M., Xu, Y., Ling, Q., Lin, W., Zhang, J., Yan, Z., Ma, J., Li, W., et al. (2023) · Drugs · doi:10.1007/s40265-023-01932-2 · Cited by 24
Darwesh, A. M., El-Azab, M. F., Abogresha, N. M., El-Sayed, N. M., & Moustafa, Y. M. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000557 · Cited by 23
Jobanputra, R., Sargeant, J. A., Almaqhawi, A., Ahmad, E., Arsenyadis, F., Webb, D. R., Herring, L. Y., Khunti, K., Davies, M. J., & Yates, T. (2023) · Obesity Reviews · doi:10.1111/obr.13553 · Cited by 22
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 23
Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 24
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 23
Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 22
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 24
Nesti, L., & Tricò, D. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.818 · Cited by 19
Wallner, M., Biber, M. E., Stolfo, D., Sinagra, G., Benson, L., Dahlström, U., Guðbjörnsdóttir, S., Cosentino, F., Mol, P. G. M., Rosano, G. M. C., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae026 · Cited by 21
Kyhl, K., Lønborg, J., Hartmann, B., Kissow, H., Poulsen, S. S., Ali, H. H. E., Kjær, A., Dela, F., Engstrøm, T., & Treiman, M. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.009 · Cited by 17
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
Staszewsky, L., Baviera, M., Tettamanti, M., Colacioppo, P., Robusto, F., D'Ettorre, A., Lepore, V., Fortino, I., Bisceglia, L., Attolini, E., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002708 · Cited by 13
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
Leveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 17
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 17
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 15
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Vaz-Salvador, P., Adão, R., Vasconcelos, I., Leite-Moreira, A. F., & Brás‐Silva, C. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07306-8 · Cited by 15
Pugliese, N. R., Pieroni, A., Biase, N. D., Fiore, V., Nesti, L., Agostoni, P., & Dini, F. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10194-7 · Cited by 14
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 13
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 12
Clinical impact of oral antidiabetic medications in heart failure patients
Palazzuoli, A., Ceccarelli, E., Ruocco, G. M., & Nuti, R. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9669-0 · Cited by 11
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y.-H. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 11
Positioning Metabolism as a Central Player in the Diabetic Heart
Mereweather, L. J., Aparicio, C. N. M., & Heather, L. C. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.92 · Cited by 11
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 11
Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment
Обрезан, А. Г., & Куликов, Н. В. (2018) · Kardiologiia · doi:10.18087/cardio.2018.7.10156 · Cited by 10
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Jiang, Y., Zhou, G., Guo, Y., & Long, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0050 · Cited by 15
Xia, J., Nong, Y., Teng, J., Mohammed, S. A., Liu, J., Pang, Y., Costantino, S., Ruschitzka, F. T., Hamdani, N., Abdellatif, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113471 · Cited by 12
Hong, T., Su, Q., Li, X., Shan, Z., Chen, L., Peng, Y., Chen, L., Yan, L., Bao, Y., Lyu, Z., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3416 · Cited by 9
Chen, C., Huang, Y., Zeng, Y., Lu, X., & Dong, G. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-01275-5 · Cited by 9
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 11
Chen, C., Peng, H., Li, M., Lu, X., Huang, M., Zeng, Y., & Dong, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664533 · Cited by 9
Huang, Y., Xu, X.-Z., Liu, J., Wang, P.-Y., Wang, X., Feng, H., Liu, C., & Han, X. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03324-6 · Cited by 9
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 8
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 8
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 9
Cardiac substrate metabolism in type 2 diabetes
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2025) · Biochemical Journal · doi:10.1042/bcj20240189 · Cited by 6
Patel, K. V., Sarraju, A., Neeland, I. J., & McGuire, D. K. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01355-5 · Cited by 7
Mather, K. J., Considine, R. V., Hamilton, L., Patel, N. A., Mathias, C. J., Territo, W. L., Goodwill, A. G., Tune, J. D., Green, M. A., & Hutchins, G. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00712 · Cited by 6
Lack of Benefit for Liraglutide in Heart Failure—Reply
Margulies, K. B., McNulty, S. E., & Cappola, T. P. (2016) · JAMA · doi:10.1001/jama.2016.15394 · Cited by 6
Metadata
- Authors
- Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Corresponding author
- Lepore, John J.
- Venue
- JACC: Heart Failure
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 4
- Issue
- 7
- Pages
- 559-566
- ISSN
- 2213-1779 (ISSN-L)
- OpenAlex
- W2335779504
- Cited by
- 165
- References
- 31
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 23 · 2023: 15 · 2022: 12 · 2021: 16 · 2020: 10 · 2019: 18 · 2018: 13 · 2017: 17 · 2016: 11
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- JACC Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline (NCT01357850)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- albiglutide, GLP-1 receptor agonists, myocardial metabolism, peak oxygen uptake, exercise capacity, left ventricular ejection fraction, cardiac function
- MeSH terms
- Walk Test, Positron Emission Tomography Computed Tomography, Adult, Aged, Carbon Radioisotopes, Chronic Disease, Echocardiography, Female, Glucose, Heart Failure, Humans, Male, Middle Aged, Myocardium, Oxygen Consumption, Quality of Life, Stroke Volume, Exercise Tolerance, Radiopharmaceuticals, Fluorodeoxyglucose F18, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
